X. Pu

Multi-Center Study of the 99th Percentile Value of High-Sensitivity Troponin I in A Normal Healthy Chinese Population

Wei Chen, Ying Cao, P. Yin, 2017 .

Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia

John D. Davis, N. Al-Huniti, M. Sale, 2021, CPT: pharmacometrics & systems pharmacology.

A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumab

John D. Davis, N. Al-Huniti, J. Bosley, 2021, CPT: pharmacometrics & systems pharmacology.

[Frequency of protein C polymorphisms in Chinese population and thrombotic patients].

B. Zhou, X. Pu, Y. Zheng, 1998, Zhonghua yi xue za zhi.

591. Adintrevimab (ADI) Population Pharmacokinetics (PPK) in Phase 1 and Phase 2/3 COVID-19 Prevention and Treatment Study Participants

P. Ambrose, C. Rubino, Myra W. Popejoy, 2022, Open Forum Infectious Diseases.

Prevalence of methylenetetrahydrofolate reductase C677T and its association with arterial and venous thrombosis in the Chinese population

X. Pu, Yanze Zheng, Jian Tong, 2000, British journal of haematology.